Structure-Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Dec 23

PMID 36551193

Authors

Rina Nakamura

Toshifumi Akizawa

Motomi Konishi

Affiliations

Soon will be listed here.

Abstract

We recently discovered JAL-TA9 (YKGSGFRMI), a short hydrolytic peptide that we termed a Catalytide. The catalytic center of JAL-TA9 was modeled using MM2 and MMFF94 parameters and identified as GSGFR. Additionally, a structure-activity relationship study showed that GSGYR cleaved Aβ11-29. Here, we developed a novel Catalytide in silico. Molecular dynamics simulations of GSGYR and RYGSG using MM2 and MMFF94 parameters suggested that both peptides may form catalytic triads and oxyanion holes. The hydrolytic potency of RYGSG was five times higher than that of GSGYR. Moreover, both peptides showed three common cleavage positions for Aβ11-29; namely, L17-V18, V18-F19, and E22-D23. The aggregation ratio analyzed by the thioflavin-T assay correlated well with proteolytic activity, suggesting that the aggregation of Aβ11-29 was suppressed by the cleavage reaction. Docking simulations with the carbonyl carbon of L17 or the carbonyl carbon of E22 in Aβ11-29 were conducted using the secondary structures of GSGYR and RYGSG. The distance between the hydroxyl group of serine and the carbonyl carbon of the two cleavage sites proved that RYGSG was closer to Aβ11-29 than to GSGYR. This study demonstrated that Catalytides are useful for understanding structure-activity relationships.

Citing Articles

An 11-mer Synthetic Peptide Suppressing Aggregation of Aβ25-35 and Resolving Its Aggregated Form Improves Test Performance in an Aβ25-35-Induced Alzheimer's Mouse Model.

Nakamura R, Matsuda A, Higashi Y, Hayashi Y, Konishi M, Saito M Biomolecules. 2024; 14(10).

PMID: 39456166 PMC: 11506537. DOI: 10.3390/biom14101234.

SKGQA, a Peptide Derived from the ANA/BTG3 Protein, Cleaves Amyloid-β with Proteolytic Activity.

Hatakawa Y, Nakamura R, Akizawa T, Konishi M, Matsuda A, Oe T Biomolecules. 2024; 14(5).

PMID: 38785993 PMC: 11118129. DOI: 10.3390/biom14050586.

Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimer's model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form.

Nakamura R, Konishi M, Higashi Y, Saito M, Akizawa T Alzheimers Res Ther. 2023; 15(1):83.

PMID: 37076912 PMC: 10114458. DOI: 10.1186/s13195-023-01229-2.

References

Hedstrom L . Serine protease mechanism and specificity. Chem Rev. 2002; 102(12):4501-24. DOI: 10.1021/cr000033x. View

Dahlgren K, Manelli A, Stine Jr W, Baker L, Krafft G, LaDu M . Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002; 277(35):32046-53. DOI: 10.1074/jbc.M201750200. View

Bulic B, Pickhardt M, Mandelkow E, Mandelkow E . Tau protein and tau aggregation inhibitors. Neuropharmacology. 2010; 59(4-5):276-89. DOI: 10.1016/j.neuropharm.2010.01.016. View

Yang X, Morita M, Wang H, Suzuki T, Yang W, Luo Y . Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity. Nucleic Acids Res. 2008; 36(21):6872-81. PMC: 2588512. DOI: 10.1093/nar/gkn825. View

McAlary L, Aquilina J, Yerbury J . Susceptibility of Mutant SOD1 to Form a Destabilized Monomer Predicts Cellular Aggregation and Toxicity but Not Aggregation Propensity. Front Neurosci. 2016; 10:499. PMC: 5095133. DOI: 10.3389/fnins.2016.00499. View

Lee E, Lee V, Trojanowski J . Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011; 13(1):38-50. PMC: 3285250. DOI: 10.1038/nrn3121. View

Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Pekarek K, Sobel R, Hauser S . Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med. 2013; 210(7):1301-9. PMC: 3698524. DOI: 10.1084/jem.20121611. View

Hatakawa Y, Nakamura R, Konishi M, Sakane T, Saito M, Akizawa T . Catalytides derived from the Box A region in the ANA/BTG3 protein cleave amyloid-β fragment peptide. Heliyon. 2019; 5(9):e02454. PMC: 6819762. DOI: 10.1016/j.heliyon.2019.e02454. View

Li J, Uversky V, Fink A . Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry. 2001; 40(38):11604-13. DOI: 10.1021/bi010616g. View

10.

Chen Y, Wang C, Wu J, Li L . BTG/Tob family members Tob1 and Tob2 inhibit proliferation of mouse embryonic stem cells via Id3 mRNA degradation. Biochem Biophys Res Commun. 2015; 462(3):208-14. DOI: 10.1016/j.bbrc.2015.04.117. View

11.

Prusiner S . Novel proteinaceous infectious particles cause scrapie. Science. 1982; 216(4542):136-44. DOI: 10.1126/science.6801762. View

12.

Sakaguchi Y, Nakamura R, Konishi M, Hatakawa Y, Toyoda H, Akizawa T . Effects of Cu on conformational change and aggregation of hPrP180-192 with a V180I mutation of the prion protein. Biochem Biophys Res Commun. 2019; 514(3):798-802. DOI: 10.1016/j.bbrc.2019.05.009. View

13.

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

14.

Nakamura R, Konishi M, Taniguchi M, Hatakawa Y, Akizawa T . The discovery of shorter synthetic proteolytic peptides derived from Tob1 protein. Peptides. 2019; 116:71-77. DOI: 10.1016/j.peptides.2019.03.005. View

15.

Kumar J, Namsechi R, Sim V . Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce Cytotoxicity. PLoS One. 2015; 10(6):e0129087. PMC: 4466325. DOI: 10.1371/journal.pone.0129087. View

16.

Horiuchi M, Takeuchi K, Noda N, Muroya N, Suzuki T, Nakamura T . Structural basis for the antiproliferative activity of the Tob-hCaf1 complex. J Biol Chem. 2009; 284(19):13244-55. PMC: 2676056. DOI: 10.1074/jbc.M809250200. View

17.

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

18.

Young L, Saunders J, Mahood R, Revill C, Foster R, Tu L . Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem. 2014; 7(1):73-81. PMC: 4280571. DOI: 10.1038/nchem.2129. View

19.

Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N . Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996; 2(8):864-70. DOI: 10.1038/nm0896-864. View

20.

Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):311-21. DOI: 10.1056/NEJMoa1312889. View